Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 8, 2022, Omega Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Meeting"). A total of 42,144,271 shares of the Company's common stock, $0.001 par value per share (the "Common Stock") were present in person or represented by proxy at the Meeting, representing approximately 88% of the Company's outstanding Common Stock as of the April 11, 2022 record date. The following are the voting results for the proposals considered and voted upon at the Meeting, each of which were described in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2022.

Item 1 - Election of two Class I directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2025 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal.




                        Votes For  Votes Withheld Broker Non-Votes

Noubar B. Afeyan, Ph.D. 37,291,057 2,369,920 2,483,294 Mahesh Karande 37,605,322 2,055,655 2,483,294

Item 2 - Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.

Votes For Votes Against Votes Abstained Broker Non-Votes 41,823,321 317,487 3,463

             -

Based on the foregoing votes, Noubar B. Afeyan, Ph.D. and Mahesh Karande were elected and Item 2 was approved.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses